HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kilpatrick, E S Search for Related Content PubMed PubMed Citation Articles by Kilpatrick, E S

HbA_1c measurement

Correspondence to:
Dr E S Kilpatrick
Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK; eric_kilpatrick@hotmail.com

Keywords: International Federation of Clinical Chemistry; glycated haemoglobin

Abbreviations: DCCT, Diabetes Control and Complications Trial; IFCC, International Federation of Clinical Chemistry; HbA_1c, glycated haemoglobin; UKPDS, United Kingdom Prospective Diabetes Study

The first 150 words of the full text of this article appear below.

It is difficult to overestimate the contribution made by glycated haemoglobin measurement (usually in the form of HbA_1c) to the management of patients with diabetes mellitus and the reliance now placed on the test by clinicians. Before its introduction as a routine test in the late 1970s and early 1980s, objectively assessing glycaemic control relied on measures such as 24 hour urine glucose excretions¹ and daily blood glucose profiles.² By comparison, measurement of HbA_1c gave a much more reliable measure of glucose control over the prolonged period of the previous six to eight weeks.³ The clinical usefulness of the test was cemented by major trials, such as the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes⁴ and the United Kingdom Prospective Diabetes Study (UKPDS) in type 2 diabetes.⁵ Both showed that improved glycaemic control, as assessed by HbA_1c, could lead to substantial reductions in . . . [Full text of this article]

This article has been cited by other articles:

				D. R Macdonald, A. M Hanson, M. R Holland, and B. M Singh Clinical impact of variability in HbA1c as assessed by simultaneously measuring fructosamine and use of error grid analysis Ann Clin Biochem, July 1, 2008; 45(4): 421 - 425. [Abstract] [Full Text] [PDF]

				R. M. Cohen, T. J. LeCaire, C. J. Lindsell, E. P. Smith, and D. J. D'Alessio Relationship of Prospective GHb to Glycated Serum Proteins in Incident Diabetic Retinopathy: Implications of the glycation gap for mechanism of risk prediction Diabetes Care, January 1, 2008; 31(1): 151 - 153. [Full Text] [PDF]

				L. Herranz, L. Saez-de-Ibarra, C. Grande, and L. F. Pallardo Non-Glycemic-Dependent Reduction of Late Pregnancy A1C Levels in Women With Type 1 Diabetes Diabetes Care, June 1, 2007; 30(6): 1579 - 1580. [Full Text] [PDF]

				R. J. Schrot, K. T. Patel, and P. Foulis Evaluation of Inaccuracies in the Measurement of Glycemia in the Laboratory, by Glucose Meters, and Through Measurement of Hemoglobin A1c Clin. Diabetes, April 1, 2007; 25(2): 43 - 49. [Abstract] [Full Text] [PDF]

				T. M Reynolds, W S. A Smellie, and P. J Twomey Glycated haemoglobin (HbA1c) monitoring BMJ, September 16, 2006; 333(7568): 586 - 588. [Full Text] [PDF]

				W S A Smellie, J Forth, D Bareford, P Twomey, M J Galloway, E C M Logan, S R S Smart, T M Reynolds, and C Waine Best practice in primary care pathology: review 3. J. Clin. Pathol., August 1, 2006; 59(8): 781 - 789. [Abstract] [Full Text] [PDF]